Protocol Ledger

NCT06891443 · Phase III · RECRUITING

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Interventional Phase III clinical trial protocol NCT06891443 sponsored by Laboratoires Thea in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-04 Enrollment: 32 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06891443
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)32 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06891443
Protocol FieldVerified Registry Value
NCT IdentifierNCT06891443
Consolidated Lead SponsorLaboratoires Thea
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment32 participants (ESTIMATED)
Registered Start Date2025-06-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06891443
Hospital Research SiteLocationSite Profile
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->
University of IowaIowa City, IAOpen Hospital Dossier ->
University of Pennsylvania Abramson Cancer CenterPhiladelphia, PAOpen Hospital Dossier ->
University of AlbertaEdmonton, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI